A phase‑2 trial of 386 participants showed a 9.4% BMI drop and a 1.5% HbA1c reduction with the semaglutide‑bimagrumab combo. Learn why this pairing could rewrite obesity care and how you can apply it.
PhilipJameson
Posted on • Originally published at weightlossfacts.online
Eliminate HbA1c Plateaus With the Secret Dual Obesity Treatment
For further actions, you may consider blocking this person and/or reporting abuse
Top comments (0)